





Florence D. Mowlem PhD
Director, eCOA
Medable



Regulatory Acceptance of Patient-Reported
Outcome (PRO) Data from Bring-Your-Own-Device
(BYOD) Solutions to Support Medical Product
Labeling Claims

June 16, 2022 11 am ET



Jennifer Goldsack, MBA
CEO
DiMe
Moderator



But first, housekeeping

- Please note today's session is being recorded
- To ask a question for discussion during Q&A, please:
 - Either 'raise your hand' in the participant window and moderator will unmute you to ask your question live, or
 - Type your question into the chat box
- Slides and recording will be available after today's session







Florence D. Mowlem PhD
Director, eCOA
Medable



Regulatory Acceptance of Patient-Reported
Outcome (PRO) Data from Bring-Your-Own-Device
(BYOD) Solutions to Support Medical Product
Labeling Claims

June 16, 2022 11 am ET



Jennifer Goldsack, MBA
CEO
DiMe
Moderator



Key Points

- Hesitation from trial sponsors due to:
 - concerns around data quality, integrity, and variability
 - regulatory acceptance uncertainties
 - lack of formal guidance around BYOD from regulators
- So, important considerations for BYOD concern the conservation of the measurement properties of validated instruments when used on screens of different sizes, and the technical and practical considerations related to use of the patient's own mobile devices or computers



Key Points



A regulatory approved labelling claim based on ePRO data collected using BYOD has occurred!!!!!

The Pfizer and BioNTech mRNA Vaccine study for the treatment of COVID-19 collected PRO safety data from over 40,000 participants worldwide using an electronic diary, with 79% of participants using their own device (BYOD) and 29% using a provisioned device.

BUT...... We need more evidence......

Sponsor	ТІ	Product name	Study phase	Endpoint position and Type	PROM	PRO endpoint	% of BYOD	ClinicalTrials.gov identifier	Approval agencies	PI link
BioNTech SE, Pfizer	COVID- 19	COMIRNATY	Phase 3	Primary safety	Solicited local and systemic reaction diary	% of participants reporting the following for 7 days after Dose1, 2, and 3: pain, redness, and swelling at injection site, fatigue, headache, muscle pain, chills, joint pain, fever, vomiting, diarrhea	79%	NCT04713553	FDA, EMA	https://w ww.fda.g ov/media/ 151707/d ownload

TI therapeutic indication, PROM patient reported outcome measure, BYOD bring your own device, PI package insert



A call to action:



Pledge your intention to contribute to a database of PRO endpoints captured via BYOD used in medical product labelling



https://lnkd.in/e-VZe7e2

Article link: https://link.springer.com/article/10.1007/s43441-022-00412-1







Florence D. Mowlem PhD Director, eCOA Medable



Springer Link

Regulatory Acceptance of Patient-Reported Outcome (PRO) Data from Bring-Your-Own-Device (BYOD) Solutions to Support Medical Product Labeling Claims

June 16, 2022 11am ET



Jennifer Goldsack, MBA **CEO** DiMe Moderator



Care Transitions Supporting Effective Virtual First Care (V1C)

Public Launch Event June 28, 2022 | 1:30 p.m. ET



Members






























































Moving from "Should Do" to "How To"

A deep dive into the DATAcc Toolkits for
Inclusivity with the creators

July 12, 2022 11am ET



Jamileh Jemison, MD, MS
Clinical Research Coordinator
MindMed



Jeanne Chung Program Lead DiMe



Justin Ranton
Director, Head of UX
AliveCor



Nicole Braccio, PharmD, RPh
Policy Analyst & Pharmacist
National Patient Advocate
Foundation



Mitchell Tang
Doctoral Student
Harvard Business School



Yashoda Sharma
Program Director
DiMe
Moderator





Micky Tripathi
National Coordinator for
Health Information
Technology, HHS
Keynote

Sensor data integrations to power better decisions, faster, across healthcare & research

Public launch event

July 18, 2021 | 10.30am - noon ET



Jennifer Goldsack
Chief Executive Officer,
Digital Medicine
Society, DiMe
Moderator



THANK YOU



